Difficulty: Medium
Average Score: 93%
Practice
Which is the first choice agent to give to a patient with Haemophilia A who has moderate factor deficiency and a retroperitoneal bleed?
Correct answer
C
Rationale
In the context of a patient with Hemophilia A experiencing a retroperitoneal bleed and moderate factor deficiency, the correct choice is C) Factor VIII concentrate. Hemophilia A is a genetic disorder characterized by a deficiency of clotting factor VIII. Factor VIII concentrate provides the specific missing clotting factor in patients with Hemophilia A, thereby promoting effective clot formation and controlling bleeding.
A) Cryoprecipitate contains a mixture of clotting factors, including Factor VIII, but Factor VIII concentrate provides a more concentrated and reliable source of the specific missing factor for more effective treatment in patients with Hemophilia A.
B) Fresh Frozen Plasma (FFP) contains various clotting factors, but it is not the first-line treatment for Hemophilia A. Factor VIII concentrate is preferred due to its targeted and specific action on the deficient factor.
D) Factor IX concentrate is used in the treatment of Hemophilia B, not Hemophilia A. Factor IX deficiency characterizes Hemophilia B, and administering Factor IX concentrate would not address the factor deficiency in a patient with Hemophilia A.
Educationally, understanding the specific factor deficiencies in Hemophilia A and B is crucial for providing targeted and effective treatment. Knowing the appropriate factor concentrates for each type of Hemophilia ensures optimal patient care and outcomes. This case highlights the importance of precision in selecting treatment options based on the underlying pathophysiology of the condition.
A) Cryoprecipitate contains a mixture of clotting factors, including Factor VIII, but Factor VIII concentrate provides a more concentrated and reliable source of the specific missing factor for more effective treatment in patients with Hemophilia A.
B) Fresh Frozen Plasma (FFP) contains various clotting factors, but it is not the first-line treatment for Hemophilia A. Factor VIII concentrate is preferred due to its targeted and specific action on the deficient factor.
D) Factor IX concentrate is used in the treatment of Hemophilia B, not Hemophilia A. Factor IX deficiency characterizes Hemophilia B, and administering Factor IX concentrate would not address the factor deficiency in a patient with Hemophilia A.
Educationally, understanding the specific factor deficiencies in Hemophilia A and B is crucial for providing targeted and effective treatment. Knowing the appropriate factor concentrates for each type of Hemophilia ensures optimal patient care and outcomes. This case highlights the importance of precision in selecting treatment options based on the underlying pathophysiology of the condition.